Director of the Oral and Maxillofacial Surgery Residency Training Program and Director of Maxillofacial Oncology
Rutgers School of Dental Medicine
Newark, New Jersey
Rabie M. Shanti, DMD, MD, is a fellowship trained and board certified oral and maxillofacial surgeon at Rutgers Health. Dr. Shanti specializes in the evaluation and surgical management of benign and malignant tumors of the head and neck. Dr. Shanti received his undergraduate degree in biological sciences (summa cum laude) from Florida Atlantic University. He obtained his D.M.D. (magna cum laude) from Harvard School of Dental Medicine, and his M.D. from Rutgers New Jersey Medical School. Dr. Shanti completed his Oral and Maxillofacial Surgery Residency at Rutgers Health/University Hospital. Subsequently, he completed a two-year clinical fellowship in head and neck oncologic surgery/microvascular reconstruction at Louisiana State University Health Sciences (Shreveport). He has also completed a two-year research fellowship at the National Institutes of Health, which was sponsored by the Howard Hughes Medical Institute. After completing his fellowship Dr. Shanti joined the faculty at the University of Pennsylvania where he served as the Associate Director of the Head and Neck Cancer Service Line. In recognition of his excellence in the clinical care of oncology patients Dr. Shanti was the recipient of the 2019 Physician Award in Relationship-Based Care Nursing Excellence Award, and the 2021 Annual Emil & Lynn Hubschman Award. Both awards are given annually to a single member of the staff of Pennsylvania Hospital, where Dr. Shanti was previously an attending/staff surgeon. In 2022, Dr. Shanti returned to Rutgers University to serve as the Director of Maxillofacial Oncology and the Director of the Oral and Maxillofacial Surgery Residency Training Program. In addition to his clinical activities, Dr. Shanti is involved in translational research. He has published over 100 peer-reviewed publications and book chapters.
Disclosure(s): No financial relationships to disclose
NS-8 - Considerations for Treatment of the MRONJ Patient
Thursday, April 18, 2024
12:45 PM – 1:45 PM PT